PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+13.07%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$87.2M
AUM Growth
+$7.34M
(+9.2%)
Cap. Flow
+$584K
Cap. Flow
% of AUM
0.67%
Top 10 Holdings %
Top 10 Hldgs %
34.9%
Holding
132
New
15
Increased
19
Reduced
50
Closed
15
Avg Time Held
1.8
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$1.1M |
| 2 |
SNAK
Inventure Foods, Inc.
SNAK
|
+$947K |
| 3 |
VYNT
Vyant Bio, Inc. Common Stock
VYNT
|
+$929K |
| 4 |
H.B. Fuller
FUL
|
+$839K |
| 5 |
Cantaloupe
CTLP
|
+$779K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NSPH
NANOSPHERE INC. COM NEW
NSPH
|
+$1.56M |
| 2 |
STJ
St Jude Medical
STJ
|
+$1.37M |
| 3 |
HDS
HD Supply Holdings, Inc.
HDS
|
+$1.25M |
| 4 |
Fastenal
FAST
|
+$1.22M |
| 5 |
Bank of America
BAC
|
+$675K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.45% |
| 2 | Technology | 13.15% |
| 3 | Industrials | 7.97% |
| 4 | Consumer Staples | 6.98% |
| 5 | Communication Services | 3.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
NeoGenomics
NEO
$2.17B
| $5.41M | 6.2% |
673,032
-24,450
| -4% | -$196K |
2013 Q2
12 quarters
|
|
|
STJ
2
DELISTED
St Jude Medical
STJ
| $5.2M | 5.96% |
66,673
-19,265
| -22% | -$1.37M |
2013 Q2
12 quarters
|
|
3
Axogen
AXGN
$2.1B
| $4.35M | 4.98% |
631,908
-1,225
| -0.2% | -$6.93K |
2013 Q3
11 quarters
|
|
4
Rockwell Medical
RMTI
$31.6M
| $3.62M | 4.15% |
4,351
+1
| +0% | +$930 |
2013 Q2
12 quarters
|
|
5
Altimmune
ALT
$453M
| $2.11M | 2.42% |
2,880
-299
| -9% | -$205K |
2013 Q2
12 quarters
|
|
|
CSII
6
DELISTED
Cardiovascular Systems, Inc.
CSII
| $2.05M | 2.35% |
111,600
+16,900
| +18% | +$264K |
2013 Q2
12 quarters
|
|
7
LeMaitre Vascular
LMAT
$1.89B
| $1.97M | 2.26% |
138,358
-7,540
| -5% | -$115K |
2013 Q2
12 quarters
|
|
8
DELISTED
BioTelemetry, Inc.
BEAT
| $1.96M | 2.25% |
120,250
| – | – |
2015 Q3
3 quarters
|
|
9
Pfizer
PFE
$167B
| $1.96M | 2.25% |
58,633
-6,377
| -10% | -$204K |
2013 Q2
12 quarters
|
|
10
ePlus
PLUS
$2.47B
| $1.81M | 2.07% |
88,400
-4,000
| -4% | -$83.1K |
2013 Q2
12 quarters
|
|
|
SNAK
11
DELISTED
Inventure Foods, Inc.
SNAK
| $1.56M | 1.79% |
199,750
+134,250
| +205% | +$947K |
2013 Q2
12 quarters
|
|
12
Eli Lilly
LLY
$1.08T
| $1.55M | 1.78% |
19,700
| – | – |
2013 Q2
12 quarters
|
|
13
IZEA Worldwide
IZEA
$40.8M
| $1.49M | 1.71% |
49,009
+13,213
| +37% | +$362K |
2016 Q1
1 quarter
|
|
|
QUMU
14
DELISTED
Qumu Corp.
QUMU
| $1.33M | 1.53% |
300,010
+164,010
| +121% | +$732K |
2013 Q4
10 quarters
|
|
15
Idexx Laboratories
IDXX
$41.4B
| $1.3M | 1.49% |
14,000
| – | – |
2013 Q3
11 quarters
|
|
16
LifeVantage
LFVN
$68.4M
| $1.27M | 1.46% |
93,482
| – | – |
2013 Q2
12 quarters
|
|
|
SVU
17
DELISTED
SUPERVALU Inc.
SVU
| $1.23M | 1.41% |
37,164
-572
| -2% | -$19.6K |
2013 Q2
12 quarters
|
|
18
AT&T
T
$157B
| $1.21M | 1.39% |
37,154
-1,986
| -5% | -$59.1K |
2015 Q3
3 quarters
|
|
19
AtriCure
ATRC
$2.9B
| $1.2M | 1.38% |
85,100
+900
| +1% | +$13.7K |
2013 Q2
12 quarters
|
|
20
Altria Group
MO
$121B
| $1.2M | 1.38% |
17,400
-1,000
| -5% | -$64K |
2015 Q4
2 quarters
|
|
21
IRIDEX
IRIX
$14.6M
| $1.2M | 1.37% |
80,800
+21,000
| +35% | +$261K |
2015 Q2
4 quarters
|
|
|
22
Boston Scientific
BSX
$61.7B
| $1.18M | 1.36% |
+50,650
| New | +$1.1M |
2016 Q2
0 quarters
|
|
|
VYNT
23
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
| $1.16M | 1.33% |
3,875
+2,642
| +214% | +$929K |
2015 Q4
2 quarters
|
|
|
ZIXI
24
DELISTED
Zix Corporation
ZIXI
| $1.14M | 1.3% |
303,539
-5,500
| -2% | -$21.4K |
2013 Q2
12 quarters
|
|
|
TEAR
25
DELISTED
TearLab Corporation
TEAR
| $1.12M | 1.29% |
175,524
+48,350
| +38% | +$354K |
2015 Q2
4 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, Perkins Capital Management held 132 positions worth $87.2M, up 9.2% from $79.9M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Perkins Capital Management's Q2 2016 filing shows 15 new, 19 increased, 50 reduced and 15 closed positions. Its largest new stake was Boston Scientific: 50,650 shares worth $1.18M. The largest sale was NANOSPHERE INC. COM NEW, an estimated $1.56M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 58% a quarter earlier, followed by Technology and Industrials.
- Perkins Capital Management's largest Q2 2016 buy was Boston Scientific: 50,650 shares worth $1.18M.
- Perkins Capital Management added most to Inventure Foods, Inc. in Q2 2016, an estimated $947K increase.
- Perkins Capital Management's biggest Q2 2016 reduction was NANOSPHERE INC. COM NEW, cutting an estimated $1.56M.
- Perkins Capital Management fully exited HD Supply Holdings, Inc. in Q2 2016, selling an estimated $1.25M.
- Perkins Capital Management's ten largest holdings make up 35% of its $87.2M portfolio in Q2 2016.
- Perkins Capital Management opened 15 new positions and closed 15 in Q2 2016.
- Perkins Capital Management's portfolio value rose 9.2% quarter-over-quarter to $87.2M.
Based on Perkins Capital Management's 13F filing for Q2 2016, filed 20 Jul 2016.